PTLA Portola Pharmaceuticals Inc.

30.41
-0.11  -0%
Previous Close 30.52
Open 30.89
Price To Book 3041
Market Cap 2,077,724,721
Shares 68,323,733
Volume 1,483,283
Short Ratio
Av. Daily Volume 1,171,521

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval noted June 23, 2017.
Bevyxxa (betrixaban)
Venous thromboembolism (VTE) Prevention
Phase 2 updated data due at ASH December 2018 noted ORR 34%; 27% CR and in the PTCL cohort ORR 26%; 7% CR.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
Prior Approval Supplement (PAS) FDA Approval announced December 31, 2018.
Andexxa
Factor Xa inhibitor reversal agent

Latest News

  1. Here's Why Portola Pharmaceuticals (NASDAQ:PTLA) Can Afford Some Debt
  2. Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  3. The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results
  4. Portola Pharmaceuticals Announces Proposed Offering of Common Stock
  5. Why Portola Pharmaceuticals Is Rocketing 10.9% Higher Today
  6. Edited Transcript of PTLA earnings conference call or presentation 7-Aug-19 8:30pm GMT
  7. Portola Pharmaceuticals Inc (PTLA) Q2 2019 Earnings Call Transcript
  8. Portola Pharmaceuticals (PTLA) Reports Q2 Loss, Tops Revenue Estimates
  9. Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
  10. Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View
  11. Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y
  12. Zoetis (ZTS) Looks Good: Stock Adds 7.6% in Session
  13. Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance
  14. Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in Europe
  15. U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa
  16. Portola Pharmaceuticals (PTLA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  17. Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
  18. Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa Inhibitors
  19. Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
  20. See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.